244 related articles for article (PubMed ID: 27403962)
1. Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
Lori L; Pasquo A; Lori C; Petrosino M; Chiaraluce R; Tallant C; Knapp S; Consalvi V
PLoS One; 2016; 11(7):e0159180. PubMed ID: 27403962
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
[TBL] [Abstract][Full Text] [Related]
3. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
[TBL] [Abstract][Full Text] [Related]
4. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
5. Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex.
Singh M; Popowicz GM; Krajewski M; Holak TA
Chembiochem; 2007 Jul; 8(11):1308-16. PubMed ID: 17582821
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression.
Bursch KL; Goetz CJ; Jiao G; Nuñez R; Olp MD; Dhiman A; Khurana M; Zimmermann MT; Urrutia RA; Dykhuizen EC; Smith BC
J Biol Chem; 2024 Apr; 300(4):107146. PubMed ID: 38460939
[TBL] [Abstract][Full Text] [Related]
7. Solution structure and acetyl-lysine binding activity of the GCN5 bromodomain.
Hudson BP; Martinez-Yamout MA; Dyson HJ; Wright PE
J Mol Biol; 2000 Dec; 304(3):355-70. PubMed ID: 11090279
[TBL] [Abstract][Full Text] [Related]
8. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
[TBL] [Abstract][Full Text] [Related]
9. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
10. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.
Miller TC; Simon B; Rybin V; Grötsch H; Curtet S; Khochbin S; Carlomagno T; Müller CW
Nat Commun; 2016 Dec; 7():13855. PubMed ID: 27991587
[TBL] [Abstract][Full Text] [Related]
11. Targeting bromodomains: epigenetic readers of lysine acetylation.
Filippakopoulos P; Knapp S
Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
[TBL] [Abstract][Full Text] [Related]
12. Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions.
Chandrasekaran R; Thompson M
Biochem Biophys Res Commun; 2007 Apr; 355(3):661-6. PubMed ID: 17320048
[TBL] [Abstract][Full Text] [Related]
13. Structure and acetyl-lysine recognition of the bromodomain.
Mujtaba S; Zeng L; Zhou MM
Oncogene; 2007 Aug; 26(37):5521-7. PubMed ID: 17694091
[TBL] [Abstract][Full Text] [Related]
14. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
[TBL] [Abstract][Full Text] [Related]
15. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
[TBL] [Abstract][Full Text] [Related]
16. The Bromodomain: A New Target in Emerging Epigenetic Medicine.
Smith SG; Zhou MM
ACS Chem Biol; 2016 Mar; 11(3):598-608. PubMed ID: 26596782
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
18. Structure and ligand of a histone acetyltransferase bromodomain.
Dhalluin C; Carlson JE; Zeng L; He C; Aggarwal AK; Zhou MM
Nature; 1999 Jun; 399(6735):491-6. PubMed ID: 10365964
[TBL] [Abstract][Full Text] [Related]
19. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3.
Gamsjaeger R; Webb SR; Lamonica JM; Billin A; Blobel GA; Mackay JP
Mol Cell Biol; 2011 Jul; 31(13):2632-40. PubMed ID: 21555453
[TBL] [Abstract][Full Text] [Related]
20. Tandem bromodomains in the chromatin remodeler RSC recognize acetylated histone H3 Lys14.
Kasten M; Szerlong H; Erdjument-Bromage H; Tempst P; Werner M; Cairns BR
EMBO J; 2004 Mar; 23(6):1348-59. PubMed ID: 15014446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
